Omeros Corporation OMER shares are trading higher by $0.49 (7 percent) at $8.10 in Thursday's session. The issue is getting a lift from data surrounding its OSM721 Phase 2 trial that showed "targeted indications for the company's MASP-2 inhibitor continue to expand."
On Monday, the issue rallied to $8.70 off the positive data, but faded to end the session at $7.60.
Over the last five trading sessions (including today), the issue has found support in the lower to middle $7 handle, with all five lows ranging from its October 14 low ($7.26) to today's low ($7.61).
So far, the rally off the low has reached $8.28, which represents its highest level since peaking on Monday. If Omeros can close over $8, it will be the first time doing so since its October 11 close of $8.61.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
